UnknownPhase 3

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

270 participantsStarted 2023-01

Plain-language summary

This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CSF cryptococcal antigen (CrAg) positive meningitis * Ability and willingness to provide informed consent * Willing to receive protocol-specified lumbar punctures Exclusion Criteria: * Glasgow Coma Scale \< 15 at time of consent * Received \>= 3 doses of amphotericin B within prior 30 days * Inability to take enteral (oral or nasogastric) medicine * Cannot or unlikely to attend regular clinic visits * Receiving chemotherapy or corticosteroids * Suspected paradoxical immune reconstitution inflammatory syndrome (IRIS) * Pregnancy or breastfeeding * Previous administration of MAT2203 * Any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments

What they're measuring

Survival

Timeframe: 2 weeks

Trial details

NCT IDNCT05541107

SponsorMatinas BioPharma Nanotechnologies, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-10

Contact for this trial

Theresa Matkovits, PhD

908-505-0975 tmatkovits@matinasbiopharma.com

View on ClinicalTrials.gov More Cryptococcal Meningitis trials